{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:59:27Z","timestamp":1790085567650,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP26fk0310535"],"award-info":[{"award-number":["JP26fk0310535"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP26fk0210157"],"award-info":[{"award-number":["JP26fk0210157"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K17039"],"award-info":[{"award-number":["20K17039"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K14999"],"award-info":[{"award-number":["23K14999"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biopha.2026.119922","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:29:39Z","timestamp":1788964179000},"page":"119922","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["High tryptophan 2,3-dioxygenase expression promotes lenvatinib resistance in hepatocellular carcinoma"],"prefix":"10.1016","volume":"203","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4137-0275","authenticated-orcid":false,"given":"Osamu","family":"Maehara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zijian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Hosoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-3184","authenticated-orcid":false,"given":"Masatsugu","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goki","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Kuzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honoka","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimitsu","family":"Meno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kitagataya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuteru","family":"Natsuizaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119922_bib1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119922_bib2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119922_bib3","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119922_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.biopha.2026.119922_bib5","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119922_bib6","article-title":"Navigating second-line therapy after immunotherapy in advanced HCC\u2730","volume":"8","author":"Vogel","year":"2026","journal-title":"JHEP Rep."},{"key":"10.1016\/j.biopha.2026.119922_bib7","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/hepr.13511","article-title":"Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria","volume":"50","author":"Sho","year":"2020","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.biopha.2026.119922_bib8","article-title":"Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma","volume":"14","author":"Yang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119922_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15123257","article-title":"Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma","volume":"15","author":"Kohya","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119922_bib10","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000527759","article-title":"Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment","volume":"12","author":"Hosoda","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.biopha.2026.119922_bib11","article-title":"Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC","volume":"7","author":"Kohya","year":"2025","journal-title":"JHEP Rep."},{"key":"10.1016\/j.biopha.2026.119922_bib12","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","article-title":"EGFR activation limits the response of liver cancer to lenvatinib","volume":"595","author":"Jin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119922_bib13","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1038\/s41598-022-12076-w","article-title":"EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells","volume":"12","author":"He","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119922_bib14","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1158\/0008-5472.CAN-21-4140","article-title":"Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma","volume":"82","author":"Hu","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119922_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/JHC.S349369","article-title":"MicroRNA-128-3p mediates lenvatinib resistance of hepatocellular carcinoma cells by downregulating c-Met","volume":"9","author":"Xu","year":"2022","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.biopha.2026.119922_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ncrna.2025.05.007","article-title":"Exosome-derived hsa_circ_0007132 promotes lenvatinib resistance by inhibiting the ubiquitin-mediated degradation of NONO","volume":"14","author":"Cao","year":"2025","journal-title":"Noncoding RNA Res."},{"key":"10.1016\/j.biopha.2026.119922_bib17","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s13402-024-01032-7","article-title":"GALNT6 drives lenvatinib resistance in hepatocellular carcinoma through autophagy and cancer-associated fibroblast activation","volume":"47","author":"Zhang","year":"2024","journal-title":"Cell Oncol (Dordr)"},{"key":"10.1016\/j.biopha.2026.119922_bib18","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1186\/s12885-025-15086-9","article-title":"EZH2 confers lenvatinib resistance in hepatocellular carcinoma by suppressing ACSL1-Mediated ferroptosis","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2026.119922_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241002","article-title":"Serum kynurenine levels are a novel biomarker to predict the prognosis of patients with hepatocellular carcinoma","volume":"15","author":"Bekki","year":"2020","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119922_bib20","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1186\/s12935-021-02228-9","article-title":"Constitutive TDO2 expression promotes liver cancer progression by an autocrine IL-6 signaling pathway","volume":"21","author":"Wu","year":"2021","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.biopha.2026.119922_bib21","article-title":"TDO2 Promotes the EMT of Hepatocellular Carcinoma Through Kyn-AhR Pathway","volume":"10","author":"Li","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119922_bib22","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.4049\/jimmunol.0903670","article-title":"An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells","volume":"185","author":"Mezrich","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2026.119922_bib23","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/15384047.2021.1939638","article-title":"FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma","volume":"22","author":"Maehara","year":"2021","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biopha.2026.119922_bib24","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/carcin\/bgx095","article-title":"Fibroblast growth factor-2-mediated FGFR\/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma","volume":"38","author":"Maehara","year":"2017","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.biopha.2026.119922_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119922_bib26","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jhep.2017.01.012","article-title":"Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC","volume":"66","author":"Lencioni","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2026.119922_bib27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1159\/000515552","article-title":"Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma","volume":"10","author":"Koroki","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.biopha.2026.119922_bib28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MEG.0000000000002466","article-title":"Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma","volume":"35","author":"Kim","year":"2023","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2026.119922_bib29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/mc.23644","article-title":"Focal adhesion kinase confers lenvatinib resistance in hepatocellular carcinoma via the regulation of lysine-deficient kinase 1","volume":"63","author":"Hou","year":"2024","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.biopha.2026.119922_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100976","article-title":"Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression","volume":"69","author":"Wang","year":"2023","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.biopha.2026.119922_bib31","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41401-022-01021-2","article-title":"Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation","volume":"44","author":"Fern\u00e1ndez-Palanca","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.biopha.2026.119922_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2025.102642","article-title":"The role of tumor microenvironment in lenvatinib resistance of hepatocellular carcinoma","volume":"49","author":"Jiang","year":"2025","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.biopha.2026.119922_bib33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119922_bib34","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1038\/s41467-020-17750-z","article-title":"Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine","volume":"11","author":"Campesato","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119922_bib35","article-title":"Global research trends in tryptophan metabolism and cancer: a bibliometric and visualization analysis (2005-2024)","volume":"15","author":"Ma","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119922_bib36","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20221682","article-title":"Tryptophan metabolism and disposition in cancer biology and immunotherapy","volume":"42","author":"Badawy","year":"2022","journal-title":"Biosci. Rep."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:01:11Z","timestamp":1790082071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226009583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"alternative-id":["S0753332226009583"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119922","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High tryptophan 2,3-dioxygenase expression promotes lenvatinib resistance in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119922","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119922"}}